
ELAB · NASDAQ
PMGC Holdings Inc.
$1.85 -0.07 (-3.65%)
Company overview
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. Its lead product, EL-22, is a first-in-class engineered probiotic approach designed to address obesity by preserving muscle mass during weight loss treatments, including GLP-1 receptor agonists. The company also engages in medical scientific research and development activities and operates investment firms. Formerly known as Elevai Labs, Inc., the company changed its name to PMGC Holdings Inc. in December 2024. Incorporated in 2020, PMGC Holdings Inc. is based in Newport Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.5M
- Employees
- 2
- Headquarters
- Newport Beach, CA
- Website
- pmgcholdings.com
- CEO
- Graydon Bensler
- Listed
- November 21, 2023
- P/E
- -0.01
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.3M
- Gross profit
- $161,304
- Operating income
- -$9.5M
- EBITDA
- -$9M
- Net income
- -$11.1M
- EPS
- -$218.85
- Total assets
- $26M
- Total debt
- $8M
- Gross margin
- 12.68%
- Net margin
- -873.11%
- Earnings yield
- -11,398.44%
No product segmentation.
Showing FY 2023
News